Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11
Equity Offering 12
GlycoMimetics Prices Public Offering of Shares for USD119 Million 12
GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14
GlycoMimetics Raises USD21 Million in Public Offering of Shares 16
GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18
GlycoMimetics Completes IPO For US$64.4 Million 19
GlycoMimetics Inc – Key Competitors 21
GlycoMimetics Inc – Key Employees 22
GlycoMimetics Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 02, 2018: GlycoMimetics reports third quarter 2018 results and highlights recent company achievements 24
Aug 09, 2018: Glycomimetics reports second quarter 2018 results and highlights recent company achievements 26
May 03, 2018: GlycoMimetics Reports First Quarter 2018 Results 27
Mar 06, 2018: GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results 28
Nov 08, 2017: GlycoMimetics Reports Program Updates and Third Quarter 2017 Results 29
Aug 03, 2017: GlycoMimetics Reports Program Updates and Second Quarter 2017 Results 31
May 08, 2017: GlycoMimetics Reports Program Updates and First Quarter 2017 Results 33
Mar 01, 2017: GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results 34
Corporate Communications 35
Jun 12, 2017: GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors 35
Mar 13, 2017: GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors 36
Product News 37
06/05/2017: GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting 37
05/17/2017: GlycoMimetics’ GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia 38
Product Approvals 39
May 25, 2017: GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia 39
Clinical Trials 40
May 30, 2018: GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy 40
Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1271 at AACR Annual Meeting 2018 41
Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1359 at AACR Annual Meeting 2018 42
Mar 05, 2018: GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML 43
Feb 08, 2018: GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Chemotherapy 44
Dec 12, 2017: GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271 45
Nov 01, 2017: GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting 46
May 18, 2017: GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML 48
May 02, 2017: GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma 50
Apr 20, 2017: GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting 51
Mar 07, 2017: GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271 52
Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1271 at AACR Annual Meeting 2017 53
Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GlycoMimetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11
GlycoMimetics Prices Public Offering of Shares for USD119 Million 12
GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14
GlycoMimetics Raises USD21 Million in Public Offering of Shares 16
GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18
GlycoMimetics Completes IPO For US$64.4 Million 19
GlycoMimetics Inc, Key Competitors 21
GlycoMimetics Inc, Key Employees 22
List of Figures
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9